Memantin

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Memantin
(IUPAC) ime
3,5-dimetiltriciklo[3.3.1.13,7]dekan-1amin
ili
3,5-dimetiladamantan-1-amin
Klinički podaci
Robne marke Namenda
AHFS/Drugs.com Monografija
MedlinePlus a604006
Identifikatori
CAS broj 19982-08-2
ATC kod N06DX01
PubChem[1][2] 4054
DrugBank DB01043
ChemSpider[3] 3914
UNII W8O17SJF3T DaY
KEGG[4] D08174 DaY
ChEMBL[5] CHEMBL807 DaY
Hemijski podaci
Formula C12H21N 
Mol. masa 179,3 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Bioraspoloživost ~100%
Metabolizam Hepatički (<10%)
Poluvreme eliminacije 60–100 sati
Izlučivanje Renalno
Farmakoinformacioni podaci
Licenca

EU EMEA:linkUS FDA:link

Trudnoća ?
Pravni status S4 (Au), POM (UK), ℞-only (U.S.)
Način primene Oralno

Memantin je lek iz adamantanske klase lekova za tretiranje Alchajmerove bolesti koji deluje na glutamatergični sistem putem blokiranja NMDA glutamatnih receptora. On je prvi put sintetisan u kompaniji Eli Lili 1968. Memantin je u prodaju pod imenima Aksura, Akatinol, Namenda, Ebiksa, Abiksa i Memoks. Uprkos dugogodišnjeg istraživanja, postoji malo dokaza da ima uticaja na blagu do umerene Alchajmerovu bolest.[6]

Reference

[uredi | uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. Schneider, LS; Dagerman, KS, Higgins, JP, McShane, R (2011). „Lack of evidence for the efficacy of memantine in mild Alzheimer disease.”. Archives of neurology 68 (8): 991–8. PMID 21482915. 

Literatura

[uredi | uredi kod]
  • Lipton SA (2005). „The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism”. Current Alzheimer research 2 (2): 155–65. DOI:10.2174/1567205053585846. PMID 15974913. 

Povezano

[uredi | uredi kod]

Spoljašnje veze

[uredi | uredi kod]